Active

Psoriatic Arthritis

Active

Ankylosing Spondylitis

Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

For moderate to severe rheumatoid arthritis (RA) in adult
MTX-IR patients1

Older woman in a harness, ziplining
Abbvie's commitment to exceptional access and product experience Abbvie's commitment to exceptional access and product experience Abbvie's commitment to exceptional access and product experience

Get started with the
Enrollment & Prescription Form

Commitment to working toward 100% commercial patient access Commitment to working toward 100% commercial patient access Commitment to working toward 100% commercial patient access

For patients with commercial insurance, preferred coverage* could mean:

  • PREDICTABLE ACCESS for commercial patients
  • STANDARD PRIOR AUTHORIZATION (PA) AND APPEALS PROCESS, potential for one-time PA/appeal approval

*Formulary Definitions: Coverage means placed on formulary without a single step edit through other biologics. For RINVOQ, this could include coverage on a non‑preferred tier which may result in a higher out‑of‑pocket cost. Preferred/Step 1 means the product is placed on the plan's preferred formulary. Non‑preferred products require a higher out‑of‑pocket cost or step edit, or are placed on a higher tier.

Access means the product is covered and not NDC blocked. Restrictions may apply.

Based on formulary status under the pharmacy benefit.

Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

Please see HUMIRA full Prescribing Information.

Commercial patients not yet covered are eligible to RINVOQ from RINVOQ Complete Commercial patients not yet covered are eligible to RINVOQ from RINVOQ Complete Commercial patients not yet covered are eligible to RINVOQ from RINVOQ Complete
Handshake

NURSE
AMBASSADORS*

Empower patients

Our Nurse Ambassadors are the heart of RINVOQ Complete and HUMIRA Complete

Nurse Ambassadors provide 1:1 support to help patients start and stay on track with their prescribed treatment plan, including:

  • Help patients understand the importance of following the treatment plan prescribed by their healthcare professional.
  • Committed to answering questions throughout the experience to help limit treatment disruptions.
  • Answer patients’ insurance questions and connect them with additional insurance expertise.
  • Identify ways for patients to save on prescription costs.
Talk to us

ACCESS
SPECIALISTS

Insurance support when needed

  • Resource with expertise on Medicare and commercial plans at a national, local, and program level so that they can educate on potential options to consider based on each patient’s unique financial situation.
  • Can educate on payer prior authorization and appeal processes so you can determine the best access option for each patient’s unique situation.
credit cards

ACCESS & SAVINGS

Help with access &
treatment affordability

COMPLETE can help your commercial patients save: 

  • With the Complete Savings Card, your eligible commercially insured patients may pay as little as $5 per month.
  • Complete may help eligible commercially insured patients experiencing initial coverage delays or denials access their prescribed therapy at no charge while coverage is established.

Please see HUMIRA full Prescribing Information.

Empowering Patients
Nurse Ambassadors, In Their Own Words

Have questions or need support over the phone?

Call 1-877-COMPLETE (1‑800‑274‑6867)

*Ambassadors do not provide medical advice and are trained to direct patients to speak with their healthcare professional about any treatment-related questions, including further referrals.

RINVOQ Complete: Terms and Conditions apply. This benefit covers RINVOQ™ (upadacitinib) alone or for RINVOQ plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for RINVOQ who meet eligibility criteria. Co‑pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government‑funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government‑funded healthcare program, patient will no longer be able to use the RINVOQ Complete Savings Card and patient must call RINVOQ Complete at 1.800.2RINVOQ to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the RINVOQ Complete program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance.

HUMIRA Complete: Terms and Conditions apply. This benefit covers HUMIRA® (adalimumab) alone or, for rheumatology patients, HUMIRA plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for HUMIRA who meet eligibility criteria. Copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government‑funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government‑funded healthcare program, patient will no longer be able to use the HUMIRA Complete Savings card and patient must call HUMIRA Complete at 1-800-4HUMIRA to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the HUMIRA Complete Program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. Please see full Terms and Conditions.

Program Details: For eligible patients, the HUMIRA Complete Savings program offers up to $12,000 in annual savings, with a monthly benefit maximum of $1,200 and an expanded benefit of $9,000 during any two-month period in the benefit year.

Arava® and Plaquenil® are registered trademarks of their respective owners.

Program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. Eligibility: Patients must be diagnosed with moderate to severe rheumatoid arthritis, have a valid prescription for RINVOQ™ and participate in a commercial insurance plan that has denied or not yet made a formulary decision for RINVOQ. Once the patient’s insurance plan has made a formulary decision and established a process for reviewing coverage requests for RINVOQ, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides RINVOQ at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage.

Commitment to working toward 100% commercial patient access Commitment to working toward 100% commercial patient access Commitment to working toward 100% commercial patient access

Help patients get the support they need to start and stay
on track with their prescribed treatment

PRACTICE FORMS AND RESOURCES

To enroll a patient in RINVOQ Complete:

1

Fill out the form with your patient
This form enrolls your patient and can be used to initiate a prescription with your patient’s preferred specialty pharmacy.

2

Fill out the patient support prescription in Section 6
This may help your commercially insured patients get access to RINVOQ if they experience a delay or denial in their insurance coverage.*

3

Fax the form to 1-678-727-0690 and to the patient's chosen specialty pharmacy
You will receive a call from an Access Specialist to discuss next steps. In addition, fax the form to your patient’s specialty pharmacy if using the Pharmacy Prescription in Section 9.

4

Inform your patient that they have been enrolled
Let your patient know that they will be receiving a call from their Nurse Ambassador.

Please see HUMIRA full Prescribing Information.

*Program is not available to patients receiving prescription reimbursement under any federal, state, or government‑funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government‑funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. Eligibility: Patients must be diagnosed with moderate to severe rheumatoid arthritis, have a valid prescription for RINVOQ™ and participate in a commercial insurance plan that has denied or not yet made a formulary decision for RINVOQ. Once the patient’s insurance plan has made a formulary decision and established a process for reviewing coverage requests for RINVOQ, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides RINVOQ at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage.

PATIENT FORMS AND RESOURCES

Once you and your patient fill in the Enrollment and Prescription Form, simply fax it to RINVOQ Complete or HUMIRA Complete and inform your patient that they will be receiving a call from their Nurse Ambassador. If you complete the Pharmacy Prescription, also fax it to your patient’s chosen specialty pharmacy.

Please see HUMIRA full Prescribing Information.

Complete app

COMPLETE APP

Track treatment

The Complete App helps patients stay on track with their prescribed RINVOQ or HUMIRA treatment by helping them:

  • Access additional resources, including a savings card for those that are eligible
  • Set up medication reminders
  • Log symptoms
  • Log medication lot number and medication expiration date
Download on the App Store
Get it on Google Play
Computer monitor, keyboard and mouse

COMPLETEPRO.COM

Streamline the Rx process

CompletePro.com enables seamless enrollment into RINVOQ Complete and HUMIRA Complete, and helps streamline the prescription process for your patients.

 

With CompletePro.com, you can:

  • Request benefits verifications
  • Complete and submit prior authorizations
  • Send prescriptions to the patient’s specialty pharmacy of choice, with the option to include a savings card
  • Receive alerts for annual reauthorizations and renewals
  • Track and monitor where patients are in the prescription process

Learn more about streamlining the prescription process with Complete Pro:

Downloadable resources Downloadable resources Downloadable resources

RINVOQ ACCESS AND REIMBURSEMENT FORMS

RINVOQ Complete is here to help your patients get timely access to RINVOQ. Along with requesting information from a RINVOQ Complete Access Specialist, you can download the forms you need to get started.

INSTRUCTIONS

Here you can download helpful guidelines and tips for completing these templates.

This information is for informational purposes only and is not intended to provide reimbursement or legal advice. The information presented here does not guarantee payment or coverage.

BILLING AND CODING

SPECIALTY PHARMACY

Please see HUMIRA full Prescribing Information.

RINVOQ SAFETY DATA

Review the well-studied safety profile of RINVOQ,
including both short- and long-term analyses

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking